Chronic hepatitis B affects more than 300 million people worldwide, and less than 10% of patients achieve a functional improvement with current treatments. VTP-300 can be the solution to this deadly disease.
A UK company has disclosed the first positive data from the Phase Ib/IIb trial of VTP-300 in the HBV002 trial, which achieved both primary and secondary endpoints in people with chronic hepatitis B virus (HBV) infection. In the study, 55 participants with chronic hepatitis B whose viral suppression was suppressed by oral antiviral therapy received VTP-300 with or without low-dose nivolumab, writes Clinical Trials Arena.
In focus. Technology emerged telegraph channel. Subscribe to not miss the latest and most interesting news from the world of science!
The results showed that VTP-300 caused a significant and sustained reduction in hepatitis B surface antigen (AHB) in patients with chronic hepatitis B; The most significant reduction was observed in patients with lower baseline AHB levels. A reduction in AGV of 0.9-1.4 log10 was observed at five and eight months after low-dose administration in patients treated with VTP-300 alone, and 0.8 after 3 days in patients treated with the drug in combination with low-dose nivolumab. was. , 6 and 9 months. The results were reported by a biotechnology company based in Oxford, England.
In the HBV002 study, it was noted that patients with lower baseline AGV levels experienced greater reductions, with an average of 1.0 log10. In two patients, AGV was not detected even for three months and continued for eight months. In addition, a T-cell immune response was observed in most patients. In particular, no class 3 adverse events or serious product-related adverse events were reported following administration of VTP-300. Bill Enright, CEO of the company that developed the drug, expressed his excitement at the safety and AGV reduction data from the HBV002 trial and expressed hope that the full dataset, including immune responses, will be presented at the EASL conference.
Current treatments achieve a functional improvement in less than 10% of people with chronic hepatitis B. On the other hand, VTP-300 has the potential to be a critical element in the functional treatment of HBV. It can potentially eliminate the need for chronic treatment. In ongoing trials, the company is investigating dosage, including an additional booster and combination approaches, with results expected by the end of the year. It is estimated that more than 300 million people worldwide are infected with hepatitis B virus, with the highest prevalence in East Asia and Africa. Unfortunately, less than 10% of patients with chronic HBV infection achieve functional improvement with current treatments. This disease and its associated complications cause approximately 820,000 deaths per year.
Previously Focus wrote about the hepatitis C vaccine Scientists are already one step closer to solving it.
Source: Focus
Ashley Fitzgerald is an accomplished journalist in the field of technology. She currently works as a writer at 24 news breaker. With a deep understanding of the latest technology developments, Ashley’s writing provides readers with insightful analysis and unique perspectives on the industry.